These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1008 related articles for article (PubMed ID: 29142131)

  • 1. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
    Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
    Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
    Lehrer AT; Chuang E; Namekar M; Williams CA; Wong TAS; Lieberman MM; Granados A; Misamore J; Yalley-Ogunro J; Andersen H; Geisbert JB; Agans KN; Cross RW; Geisbert TW
    Front Immunol; 2021; 12():703986. PubMed ID: 34484200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge.
    Woolsey C; Cross RW; Agans KN; Borisevich V; Deer DJ; Geisbert JB; Gerardi C; Latham TE; Fenton KA; Egan MA; Eldridge JH; Geisbert TW; Matassov D
    PLoS Negl Trop Dis; 2022 May; 16(5):e0010433. PubMed ID: 35622847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
    Geisbert TW; Geisbert JB; Leung A; Daddario-DiCaprio KM; Hensley LE; Grolla A; Feldmann H
    J Virol; 2009 Jul; 83(14):7296-304. PubMed ID: 19386702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.
    Mire CE; Miller AD; Carville A; Westmoreland SV; Geisbert JB; Mansfield KG; Feldmann H; Hensley LE; Geisbert TW
    PLoS Negl Trop Dis; 2012; 6(3):e1567. PubMed ID: 22448291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
    Callendret B; Vellinga J; Wunderlich K; Rodriguez A; Steigerwald R; Dirmeier U; Cheminay C; Volkmann A; Brasel T; Carrion R; Giavedoni LD; Patterson JL; Mire CE; Geisbert TW; Hooper JW; Weijtens M; Hartkoorn-Pasma J; Custers J; Grazia Pau M; Schuitemaker H; Zahn R
    PLoS One; 2018; 13(2):e0192312. PubMed ID: 29462200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus.
    Mire CE; Matassov D; Geisbert JB; Latham TE; Agans KN; Xu R; Ota-Setlik A; Egan MA; Fenton KA; Clarke DK; Eldridge JH; Geisbert TW
    Nature; 2015 Apr; 520(7549):688-691. PubMed ID: 25853476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Highly Attenuated Panfilovirus VesiculoVax Vaccine Rapidly Protects Nonhuman Primates Against Marburg Virus and 3 Species of Ebola Virus.
    Woolsey C; Borisevich V; Agans KN; O'Toole R; Fenton KA; Harrison MB; Prasad AN; Deer DJ; Gerardi C; Morrison N; Cross RW; Eldridge JH; Matassov D; Geisbert TW
    J Infect Dis; 2023 Nov; 228(Suppl 7):S660-S670. PubMed ID: 37171813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.
    Geisbert TW; Feldmann H
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1075-81. PubMed ID: 21987744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.
    Marzi A; Engelmann F; Feldmann F; Haberthur K; Shupert WL; Brining D; Scott DP; Geisbert TW; Kawaoka Y; Katze MG; Feldmann H; Messaoudi I
    Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1893-8. PubMed ID: 23319647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques.
    Camargos VN; Rossi SL; Juelich TL; Smith JK; Vasilakis N; Freiberg AN; Nichols R; Fusco J
    Viruses; 2024 Jul; 16(8):. PubMed ID: 39205155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.
    Mire CE; Geisbert JB; Marzi A; Agans KN; Feldmann H; Geisbert TW
    PLoS Negl Trop Dis; 2013; 7(12):e2600. PubMed ID: 24367715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death.
    Cross RW; Xu R; Matassov D; Hamm S; Latham TE; Gerardi CS; Nowak RM; Geisbert JB; Ota-Setlik A; Agans KN; Luckay A; Witko SE; Soukieh L; Deer DJ; Mire CE; Feldmann H; Happi C; Fenton KA; Eldridge JH; Geisbert TW
    J Clin Invest; 2020 Jan; 130(1):539-551. PubMed ID: 31820871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.
    Falzarano D; Feldmann F; Grolla A; Leung A; Ebihara H; Strong JE; Marzi A; Takada A; Jones S; Gren J; Geisbert J; Jones SM; Geisbert TW; Feldmann H
    J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1082-9. PubMed ID: 21987745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs.
    Mire CE; Geisbert JB; Versteeg KM; Mamaeva N; Agans KN; Geisbert TW; Connor JH
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S384-8. PubMed ID: 25957964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
    Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
    Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thermostable bivalent filovirus vaccine protects against severe and lethal Sudan ebolavirus and marburgvirus infection.
    To A; Wong TAS; Ball AH; Lieberman MM; Yalley-Ogunro J; Cabus M; Nezami S; Paz F; Elyard HA; Borisevich V; Agans KN; Deer DJ; Woolsey C; Cross RW; Geisbert TW; Donini O; Lehrer AT
    Vaccine; 2024 Jan; 42(3):598-607. PubMed ID: 38158300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for immunisation against Marburg and Ebola viruses.
    Geisbert TW; Bausch DG; Feldmann H
    Rev Med Virol; 2010 Nov; 20(6):344-57. PubMed ID: 20658513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.